In the video Dr. Gupta summarized the results of the RE-CIRCUIT study confirming the safety profile of dabigatran also in the setting of catheter ablation in AF patients. He explains that based on the RE-CIRCUIT results, interruption of dabigatran prior to ablation is no longer warranted, as reflected in current expert guidance for performing AF ablation and shows how the broad availability of a reversal agent may provide additional reassurance for physicians to implement the uninterrupted treatment with dabigatran in this setting